Patients with gender dysphoria are increasingly seeking gender-affirming therapies, which can have adverse hematologic effects. For example, estrogen can increase the risk for arterial and venous thrombosis, whereas testosterone can cause erythrocytosis. This article reviews the hematologic issues associated with gender-affirming hormone therapies and discusses ways to lessen and monitor the risks. Common consult scenarios are also addressed.
|Original language||English (US)|
|Number of pages||8|
|Journal||Clinical Advances in Hematology and Oncology|
|State||Published - Aug 2022|
ASJC Scopus subject areas